Efficacy and Safety of Sitagliptin/Metformin Fixed-Dose Combination (FDC) Compared to Glimepiride in Participants With Type 2 Diabetes Mellitus (MK-0431A-202)
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 292 participants.
Also called NCT00993187
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 292 participants
- Sponsor
- Registry
-
NCT00993187
-
- Other papers using this trial's data
- Efficacy and safety of sitagliptin/metformin fixed-dose combination compared with glimepiride in patients with type 2 diabetes: A multicenter randomized double-blind study
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- Not reported
- Registry status
- Completed
Technical summary
Registry record NCT00993187. Randomized; double masking; primary purpose treatment. Start 2010-05-04 (actual); primary completion 2013-10-29 (actual). Results posted on 2014-09-15.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy and Safety of Sitagliptin/Metformin Fixed-Dose Combination (FDC) Compared to Glimepiride in Participants With Type 2 Diabetes Mellitus (MK-0431A-202)
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Drug)
- Sitagliptin/Metformin FDC
- Intervention (Drug)
- Comparator: Glimepiride
- Intervention (Drug)
- Matching placebo to Sitagliptin/Metformin FDC
- Intervention (Drug)
- Matching placebo to glimepiride
- Lead sponsor
- Merck Sharp & Dohme LLC
Record details
- Record id
cardio:ct-nct00993187- Content hash
7467eca3f0f6196019dad8b2c1f584a3e0d67d3083db62b3e53b8e3ed6bb2b57